MAESTRO-NASH topline results: Resmetirom induces NASH resolution, fibrosis improvement

Topline findings from the phase 3 MAESTRO-NASH trial showed that resmetirom at both 100 mg and 80 mg doses improved resolution of nonalcoholic steatohepatitis without worsening fibrosis, Madrigal Pharmaceuticals announced.This phase 3 data could place resmetirom, an oral thyroid hormone receptor-beta selective agonist, in a strong lead in the race among rival drug developers to develop the first pharmacotherapy approved for patients with NASH.“NASH with liver fibrosis puts patients at risk of progressing to liver failure, liver cancer, need for liver transplant and premature mortality;Read More

Generated by Feedzy